Trial Profile
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Endometrial cancer; Oesophageal cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms MIME-A
- 22 Dec 2023 Status changed from active, no longer recruiting to completed.
- 28 Nov 2023 Planned End Date changed from 21 Oct 2023 to 21 Dec 2023.
- 07 Jul 2023 Planned End Date changed from 21 Mar 2023 to 21 Oct 2023.